[MLL-rearranged leukemia and menin inhibitors].

Authors

Akihiko Yokoyama

Published in

[Rinsho ketsueki] The Japanese journal of clinical hematology. Volume 67. Issue 7. Pages 741-748.

Abstract

Gene rearrangements of the human MLL gene (also known as KMT2A) cause leukemia with poor prognosis by generating MLL fusion oncoproteins. MLL is an epigenetic regulator that has an evolutionarily conserved role maintaining expression of homeotic (HOX) genes during embryonic development. HOX genes and other MLL target genes such as MEIS1 block differentiation and promote proliferation in hematopoietic cells. MLL gene rearrangements generate a constitutively active version of the wild-type protein, which causes overexpression of HOX genes and other target genes, leading to leukemic transformation of normal hematopoietic progenitors. MLL fusion proteins need to form a complex with endogenous menin protein to function as an oncogenic driver. Recently, small compounds that inhibit menin-MLL interaction have been developed and used in clinics in the United States. This review explains how menin inhibitors disrupt MLL fusion protein activity and discusses potential future developments.

PMID:
42543643
Bibliographic data and abstract were imported from PubMed on 03 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.